ADAP Advocacy has released a white paper examining the 340B Drug Pricing Program, arguing that the program has drifted from its original legislative intent and now prioritizes provider interests over patient needs. The paper, titled "340B Program: The Glue That Should Hold Our Healthcare System Together," calls for reforms to increase transparency and accountability.
The 340B Program is the second-largest federal prescription drug program in the United States, behind Medicare Part D. However, according to the white paper, its rapid growth has outpaced the ability to measure how it actually helps patients. The program was designed to expand access to care and reduce financial burden for low-income patients, but the paper raises three central questions: why patients are increasingly unable to afford care, why 340B is not adequately addressing this problem, and why it is failing the uninsured and underinsured it was meant to serve.
Brandon M. Macsata, CEO of ADAP Advocacy, stated that there is an ongoing effort to push for greater transparency across the healthcare system, including hospital billing practices and pharmacy benefit managers' spread pricing policies. "The 340B Program shouldn't be excluded from this broader effort," he said, "especially since the ultimate goal is improved program efficiency, leading to greater access to care and treatment for low-income patients."
The white paper argues that a program of this size and importance cannot be entrusted to good faith alone. "Improved accountability and transparency guardrails are needed to ensure its success and ultimately its intended beneficiaries: patients," the paper reads. The full white paper is available at ADAP Advocacy's policy center.
The implications of this report are significant for patients, healthcare providers, and policymakers. For patients, particularly those with low incomes or living with HIV/AIDS, the white paper highlights that the 340B program may not be delivering on its promise of affordable care. For providers, it suggests that hospitals and other covered entities may be benefiting financially without passing savings to patients. For policymakers, the report adds to growing calls for reform of the 340B program, including increased oversight and data collection to ensure compliance with its original mission.
ADAP Advocacy's mission is to promote and enhance the AIDS Drug Assistance Programs and improve access to care for persons living with HIV/AIDS. The organization works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness and foster greater community collaboration.
